Kazia Therapeutics shares are trading higher after the company announced the presentation of data from a Phase I study evaluating concurrent paxalisib and radiation therapy in patients for the treatment of solid tumor brain metastases or leptomeningeal metastases harboring PI3K pathway mutations at the American Society for Radiation Oncology 66th Annual Meeting.
Portfolio Pulse from Benzinga Newsdesk
Kazia Therapeutics shares rose following the presentation of positive Phase I study data on paxalisib combined with radiation therapy for treating certain brain metastases at a major oncology conference.
October 02, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kazia Therapeutics shares increased after presenting positive data from a Phase I study on paxalisib combined with radiation therapy for treating brain metastases at a major oncology conference.
The presentation of positive Phase I study data at a significant oncology conference likely boosted investor confidence in Kazia Therapeutics' product pipeline, leading to a rise in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100